Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 11/20 | 0.45 |
| ▸ | DRD5 | P21918 | 9/20 | 0.45 |
| ▸ | DRD2 | P14416 | 9/20 | 0.45 |
| ▸ | DRD3 | P35462 | 8/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 7/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002166 | 0.82 | ALDH1A1 (0.45) | DRD2CHRM1DRD4HTR3EHTR3B | |
| SCHEMBL6309067 | 0.74 | HRH3 (0.58) | — | |
| SCHEMBL6305520 | 0.73 | RAB9A (0.58) | CHRM1 | |
| SCHEMBL6306116 | 0.69 | DRD1 (0.41) | DRD1DRD5DRD2DRD3CHRM1 | |
| SCHEMBL11085991 | 0.66 | PBRM1 (0.50) | DRD1DRD5DRD2DRD3PBRM1 | |
| SCHEMBL10157047 | 0.65 | DRD1 (0.85) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL17659123 | 0.65 | DRD2 (0.51) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL29678628 | 0.65 | PBRM1 (0.53) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL1037654 | 0.65 | PBRM1 (0.53) | DRD1DRD5DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL6530379 | 0.64 | DRD1 (0.81) | DRD1DRD5DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080090-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2005-04-14 | — | — | US | disclosed |
| EP-0767782-B1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-10-31 | — | — | EP | disclosed |
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | CHENARD BERTRAND L (US) | 2001-06-21 | — | — | US | disclosed |
| EP-0689536-B1 | NAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6166020-A | Aryl and heteroaryl alkoxynaphthalene derivatives | PFIZER INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0701819-B1 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5821245-A | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0795328-A1 | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5597826-A | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0701819-A2 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1996000720-A1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-11 | — | — | WO | disclosed |
| WO-1994021619-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | HTR4, HCRTR2, CNR2 | DRD1 224/4885DRD5 399/4885DRD2 144/4885 |
| US-20050080090-A1 | Naphthalene derivatives | HTR4, NPY4R, HCRTR1 | DRD1 151/4885DRD5 244/4885DRD2 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.